Skip to main content
Retour
Watch Compare

BriaCell Therapeutics Corp.

Qualité des données : 83%
Également cotée sous BCTXL Nasdaq BCTXZ Nasdaq
BCTX
Nasdaq Manufacturing Chemicals
4,60 €
▲ 0,17 € (3,84%)
Cap. Boursière: 33,21 M
Prix
4,60 €
Cap. Boursière
33,21 M
Fourchette du Jour
4,33 € — 4,61 €
Fourchette 52 Semaines
3,60 € — 98,20 €
Volume
192 824
Ouverture 4,33 €
Moyenne 50J / 200J
4,16 €
10,68% above
Moyenne 50J / 200J
9,42 €
51,17% below

Quick Summary

Points Clés

Negative free cash flow of -31,42 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-149,82%
En dessous de la moyenne du secteur (-53,41%)
ROIC-120,91%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio10,10
Interest Coverage-831,19

Valorisation

PE (TTM)
-1,12
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio1,10
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -1,1 -1,5
P/B 1,1 1,6
ROE % -149,8 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -29,64 M
ROE -149,82% ROA -127,01%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -31,42 M
ROIC -120,91% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 10,10
Interest Coverage -831,19 Asset Turnover N/A
Working Capital 28,99 M Tangible Book Value 30,21 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,12 Forward P/E N/A
P/B Ratio 1,10 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -94,63%
Market Cap 33,21 M Enterprise Value 3,30 M
Per Share
EPS (Diluted TTM) -63,33 Revenue / Share N/A
FCF / Share -4,35 OCF / Share -4,29
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 106,03%
SBC-Adj. FCF -32,50 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Revenue — — — —
Net Income -26,31 M -4,79 M -20,30 M -26,84 M
EPS (Diluted) -62,19 -0,29 -1,30 —
Gross Profit — — — —
Operating Income -27,20 M -33,33 M -23,27 M -15,29 M
EBITDA — — — —
R&D Expenses 21,27 M 27,18 M 15,34 M 8,02 M
SG&A Expenses — — — —
D&A — — — 15 272,0
Interest Expense 36 979,0 — 979,0 979,0
Income Tax — — — 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Total Assets 21,65 M 5,87 M 27,16 M 42,58 M
Total Liabilities — — — —
Shareholders' Equity 17,33 M -2,68 M -3,78 M 10,33 M
Total Debt — — — —
Cash & Equivalents 10,49 M 862 089,0 21,25 M 41,04 M
Current Assets 19,93 M 3,65 M 26,95 M 42,35 M
Current Liabilities 3,98 M 7,46 M 1,80 M 941 087,0